Early pregnancy factor has immunosuppressive and growth factor properties.
Early pregnancy factor (EPF) was first described as a pregnancy-associated substance, although recent studies suggest a more general link with cell development. It is a product of actively dividing cells and its apparent functional importance to them suggests its potential as a regulator of cell proliferation. The recent discovery of EPF in platelets has provided a comparatively rich and readily available source of EPF. The purification procedures employed to isolate EPF from this source have also been applied to pregnancy serum and urine, medium conditioned by oestrous mouse ovaries (stimulated with prolactin and embryo-conditioned medium), medium conditioned by tumour cells, and serum from rats 24 h after partial hepatectomy (PH). In all instances, biological activity followed the same pattern throughout. Furthermore, the final active reversed-phase high-performance liquid chromatography fraction from all sources was bound specifically by immobilized anti-EPF monoclonal antibodies (MAbs), indicating that the active fractions produced from these diverse sources are very closely related, if not identical. Some differences have been observed in the behaviour of EPF in various conditions. EPF is produced by proliferating tumour cells and by liver cells post-PH, and passive immunization studies with anti-EPF MAbs have shown that these cells need EPF for survival. In contrast, EPF has not been detected as a product of the pre-embryo, and addition of anti-EPF MAbs to embryo cultures does not adversely affect development from the 2-cell to the blastocyst stage. Although the pre-embryo is not dependent on EPF for its development in vitro, neutralization of EPF in vivo by anti-EPF MAbs retards its development. Thus, EPF appears to play an indirect role in maintaining the pre-embryo. By virtue of its ability to suppress the delayed-type hypersensitivity reaction, it has been suggested that EPF might act as an immunological response modifier of the maternal immune system. Alternatively, the effect of EPF on lymphocytes may be to reduce the expression of all or some cytokines and this could inhibit development. Whether or not EPF acts more directly as an autocrine growth factor from around the time of implantation, when the embryo first begins synthesis of EPF, is not known and remains to be investigated.
Morton
H
H
Department of Surgery, University of Queensland, Royal Brisbane Hospital, Australia.
Cavanagh
A C
AC
Athanasas-Platsis
S
S
Quinn
K A
KA
Rolfe
B E
BE
D000818:Animals; D001792:Blood Platelets / Q000737:chemistry; D018835:Chaperonin 10; D047108:Embryonic Development / Q000187:drug effects; D005260:Female; D006133:Growth Substances / Q000494:pharmacology / Q000502:physiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008297:Male; D051379:Mice; D010455:Peptides / Q000302:isolation & purification / Q000494:pharmacology* / Q000502:physiology; D011247:Pregnancy; D011257:Pregnancy Proteins; D012397:Rosette Formation; D013491:Suppressor Factors, Immunologic; D014407:Tumor Cells, Cultured / Q000187:drug effects
D018835:Chaperonin 10; D006133:Growth Substances; D007166:Immunosuppressive Agents; D010455:Peptides; D011257:Pregnancy Proteins; D013491:Suppressor Factors, Immunologic; C025124:early pregnancy factor